The study on madecassoside found that it could ameliorate drug-induced acute liver failure by reducing inflammation (TNF-α ↓, IL-1β ↓, IL-6 ↓, iNOS ↓, COX-2 ↓) and oxidative stress (SOD ↑, CAT ↑, GPx ↑, Nrf2 ↑, HO-1 ↑) (Wang W. et al., 2018). This evidence concerns the gene NFE2L2 and acute liver failure.